KEGG   DRUG: COVID-19 vaccine (Ad26.COV2-S [recombinant])
Entry
D12129                      Drug                                   

Name
COVID-19 vaccine (Ad26.COV2-S [recombinant]);
Janssen COVID-19 vaccine;
Covid-19 vaccine Janssen (TN)
Product
  Other
Class
Antiviral
 DG03172  COVID-19 vaccine
Remark
Product: D12129<US>
Efficacy
Active immunization (SARS-CoV-2)
  Disease
Prevention of COVID-19 [DS:H02398]
Target
SARS-CoV-2 spike glycoprotein [KO:K24152]
  Pathway
ko03230  Viral genome structure
ko05171  Coronavirus disease - COVID-19
Brite
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D12129
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D12129
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12129
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system